No Evidence of QT Prolongation With Supratherapeutic Doses of Aleglitazar

被引:2
|
作者
Sturm, Stefan [1 ]
Bentley, Darren [3 ]
Jordan, Paul [2 ]
Russell-Yarde, Fiona [4 ]
Ruf, Thorsten [1 ]
机构
[1] F Hoffmann La Roche & Cie AG, pRED, Pharma Res & Early Dev, Clin Pharmacol, Basel, Switzerland
[2] F Hoffmann La Roche & Cie AG, pRED, Pharma Res & Early Dev, Biostat, Basel, Switzerland
[3] Roche Prod Ltd, pRED, Pharma Res & Early Dev, Welwyn Garden City AL7 3AY, Herts, England
[4] FRY Med Commun Ltd, Royston, Herts, England
关键词
aleglitazar; PPAR-alpha/gamma agonist; QT interval; TYPE-2; DIABETES-MELLITUS; QT/QTC INTERVAL; FOLLOW-UP; MORTALITY; AGONISTS;
D O I
10.1097/FJC.0b013e3182411e67
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aleglitazar is a dual peroxisome proliferator-activated receptor (PPAR)-alpha/gamma agonist in clinical development, designed to offer a balanced activation of PPAR-alpha and PPAR-gamma. A phase 2 trial has demonstrated improvements in dyslipidemia and glycemic control and reduction of cardiovascular risk markers in patients with type 2 diabetes mellitus treated with aleglitazar. This study evaluated whether supratherapeutic doses of aleglitazar affect cardiac repolarization, as detected by changes in the QT interval. Healthy subjects were randomized to receive single oral doses of placebo, 300 mu g aleglitazar, 3000 mu g aleglitazar, and 400 mg moxifloxacin, in 1 of 4 sequences. Triplicate 12-lead electrocardiogram measurements were recorded predose and regularly (0.75-72 hours) after each treatment. The primary outcome was measurement of QT interval using a study-specific correction factor for heart rate. Administration of aleglitazar (300 mu g and 3000 mu g) did not cause any significant QT prolongation and after aleglitazar treatment any mean increases from placebo were <5 msec, at all time points. There was a trend for aleglitazar to cause a small dose-dependent decrease in QT interval using a study-specific correction factor for heart rate. The incidence of adverse events was similar with aleglitazar (18%-20%) and placebo (26%). Single supratherapeutic doses of aleglitazar are not associated with prolongation of the QT interval corrected for heart rate.
引用
收藏
页码:288 / 297
页数:10
相关论文
共 50 条
  • [41] Fluoroquinolones and QT prolongation
    Fan, Ellen
    CANADIAN PHARMACISTS JOURNAL, 2005, 138 (04) : 51 - 54
  • [42] QT dispersion: An electrocardiographic derivative of QT prolongation
    Krahn, AD
    Nguyen-Ho, P
    Klein, GJ
    Yee, R
    Skanes, AC
    Suskin, N
    AMERICAN HEART JOURNAL, 2001, 141 (01) : 111 - 116
  • [43] QT interval analyses from a placebo and positive controlled study evaluating the electrophysiological effects of duloxetine at supratherapeutic doses.
    Zhang, L
    Derby, M
    Gonzales, C
    Chappell, J
    Lucas, R
    Small, D
    Knadler, MP
    Callaghan, JT
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P12 - P12
  • [44] Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects
    Grange, S.
    Schmitt, C.
    Banken, L.
    Kuhn, B.
    Zhang, X.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (11) : 648 - 655
  • [45] Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy
    Roy, Andrew K.
    McCarthy, Catherine
    Kiernan, Gareth
    McGorrian, Catherine
    Keenan, Eamon
    Mahon, Niall G.
    Sweeney, Brion
    ADDICTION, 2012, 107 (06) : 1132 - 1139
  • [46] Evaluation of the Effect of Mericitabine at Projected Therapeutic and Supratherapeutic Doses on Cardiac Repolarization in Healthy Subjects: A Thorough QT/QTc Study
    Chen, Ya-Chi
    Haznedar, Joshua
    Kulkarni, Rohit
    Vistuer, Christelle
    Washington, Carla
    Liu, Mei
    Smith, Patrick
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (03): : 179 - 186
  • [47] QT PROLONGATION AND ARRHYTHMIA SUPPRESSION
    RODEN, DM
    WOOSLEY, RL
    AMERICAN HEART JOURNAL, 1985, 109 (02) : 411 - 415
  • [48] HEREDITARY PROLONGATION OF QT INTERVAL
    JOHANSSON, BW
    JORMING, B
    BRITISH HEART JOURNAL, 1972, 34 (07): : 744 - +
  • [49] Multifactorial QT interval prolongation
    Digby, Genevieve
    MacHaalany, Jimmy
    Malik, Paul
    Methot, Michelle
    Simpson, Christopher S.
    Redfearn, Damian
    Baranchuk, Adrian
    CARDIOLOGY JOURNAL, 2010, 17 (02) : 184 - 188
  • [50] QT PROLONGATION IN CANCER THERAPY
    Eng, Anne
    ONCOLOGY NURSING FORUM, 2019, 46 (02)